Together with evidence that “vertical” RAF/MEK blockade was synthetically lethal in KRAS-mut contexts [19], such background prompted us to select NSCLC and PDAC, two diseases where KRAS mutations are frequent and bear important clinical consequences, as the main target of our analysis. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.